Investigational drug · Phase 2
Adjuvanted RSVPreF3 vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiovascular Disease, Respiratory Syncytial Virus Infections.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Adjuvanted RSVPreF3 vaccine"
First trial start
2025
Aug 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Adjuvanted RSVPreF3 vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cardiovascular Disease
- Respiratory Syncytial Virus Infections
Approved drugs for the same conditions: RSV · Cardiovascular and metabolic · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Adjuvanted RSVPreF3 vaccine" as an intervention, largest first.
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and AbovePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05568797 · 1,045 participants · Start Oct 14, 2022 · Primary completion Feb 17, 2023
Drug: RSVPreF3 OA vaccine; FLU vaccine · For: Respiratory Syncytial Virus Infections
Sites: Edegem, Belgium; Erpent, Belgium; Genk, Belgium · 37 sites in all
- A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular EventsPivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07712380 · 450 participants (planned) · Start Oct 23, 2026 · Primary completion May 2, 2029
Drug: Adjuvanted RSVPreF3 vaccine · For: Cardiovascular Disease
- Immunogenicity of RSVPreF3 Vaccine in Immunocompromised PersonsPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT07050732 · 170 participants (planned) · Start Dec 4, 2025 · Primary completion Apr 2027
Drug: Arexvy (2 doses total); Arexvy (3 doses total) and 1 more · For: Respiratory Syncytial Virus (RSV)
Sites: Baltimore, Maryland
GlaxoSmithKlineGSK (GSK)
NCT07092865 · 168 participants · Start Aug 6, 2025 · Primary completion Jan 12, 2027
Drug: Adjuvanted RSVPreF3 vaccine · For: Respiratory Syncytial Virus Infections
Sites: Lexington, Kentucky; St Louis, Missouri; Omaha, Nebraska · 38 sites in all
GlaxoSmithKlineGSK (GSK)
NCT04657198 · 126 participants · Start Dec 9, 2020 · Primary completion Jun 3, 2021
Drug: RSVPreF3 OA investigational vaccine (GSK3844766A) · For: Respiratory Syncytial Virus Infections
Sites: Lenexa, Kansas; Elkridge, Maryland; Omaha, Nebraska · 10 sites in all
- RSV Immunogenicity Study in the Elderly (RISE)Pivotal-lookingActive, not recruiting
Karin Karin LoréAcademic, hospital or other
NCT07203365 · 75 participants · Start Aug 25, 2025 · Primary completion May 31, 2027
Drug: This study examines immune response differences Arexvy between individuals aged 80+ and adults aged 60-65 · For: RSV Immunisation
Sites: Saltsjöbaden, Sweden; Stockholm, Sweden
Newest research
PubMed records naming it or its code names, newest first.
- Vaccine profile of adjuvanted RSVPreF3 in adults: prevention of RSV-related lower respiratory tract disease and emerging evidence of potential cardiovascular and respiratory benefits.
Dezutter N, Theiss-Nyland K, David MP, et al. · Expert Rev Vaccines 2026
- AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance.
Tregunno C, Deraedt Q, Cuadripani S, et al. · Drug Saf 2026
- Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.
Fonseca MJ, Bratkovik S, Çolak Y, et al. · Expert Rev Vaccines 2026
- Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50-59ߙyears at increased risk of severe RSV disease and those aged ࣙ60ߙyears.
Tajima K, Zarkadoulas E, Simons J, et al. · Expert Rev Vaccines 2026
- Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy.
Puggina A, Rumi F, Zarkadoulas E, et al. · Expert Rev Vaccines 2026
- Reply to letter to editor "Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50ߙyears and older in Germany".
Waize M, Marijic P, Marijam A, et al. · Expert Rev Vaccines 2026
Also in development for Cardiovascular Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- AZD0780Phase 36 trials
AstraZeneca · Cardiovascular Disease, Dyslipidaemia, Heterozygous Familial Hypercholesterolaemia
- OlpasiranAMG 890Phase 33 trials
Amgen · Cardiovascular Disease, Atherosclerotic Cardiovascular Disease
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- VERVE-102LY4636581Phase 21 trial
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.